advertisement
Abstract #6700 Published in IGR 4-1
Dorzolamide and ocular blood flow in previously untreated glaucoma patients: a controlled double-masked study
Bergstrand IC; Heijl A; Harris AActa Ophthalmologica Scandinavica 2002; 80: 176-182
PURPOSE: The aim of this study was to investigate the hemodynamic effects of topical dorzolamide treatment in eyes with newly detected and previously untreated glaucoma. METHODS: Forty-seven patients with open-angle glaucoma were consecutively randomized to dorzolamide versus placebo TID during a six-week double-masked treatment trial. Ocular blood flow was investigated at baseline and on therapy using color Doppler imaging of the retrobulbar vessels, and scanning laser ophthalmoscope fluorescein angiograms of the retinal circulation. RESULTS: None of the flow parameters, retrobulbar or retinal, changed significantly on therapy when the results were analyzed with the Bonferroni method. Analysis with non-simultaneous tests also failed to reveal any significant changes either in retrobulbar flow velocities in the central retinal artery, ophthalmic artery, or in the short posterior ciliary arteries, or in the retinal parameters (arm-retina time, arteriovenous passage time, mean dye velocity, or macular capillary velocity), while capillary velocities at the optic disc decreased significantly in the dorzolamide group (p = 0.03). intraocular pressure reduction was significantly more pronounced in the dorzolamide group (p = 0.002), with -4.8 ± 2.9 mmHg (p < 0.0001) versus -1.8 ± 3.0 mmHg in the placebo group (p = 0.006). CONCLUSION: The present study did not indicate any measurable vascular effects from topical dorzolamide treatment in previously untreated glaucoma eyes.
Dr. I.C. Bergstrand, Department of Ophthalmology, Malmo University Hospital, Malmo, Sweden
Classification:
6.11 Bloodflow measurements (Part of: 6 Clinical examination methods)
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
